Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Empower your strategies with our Net Present Value Model: BeiGene Ltd’s BGB-16673 report and make more profitable business decisions.

Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.

Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.

 width=

BeiGene Ltd’s BGB-16673 Drug Details:

BGB-16673 is under development for the treatment of relapsed and refractory marginal zone lymphoma, follicular lymphoma, and Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma and mantle cell lymphoma. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) which acts by targeting Bruton tyrosine kinase (BTK) and cereblon (CRBN).

Report Coverage

GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.

Scope of Report

  • Drug Name
  • Administration Pathway
  • Therapeutic Areas
  • Key Manufacturers
  • Drug Development Status
  • Patent law
  • Known and Projected regulatory approval processes
  • Cash flows
  • Potential applicable patients
  • Drug margins
  • Company expenses
  • Pricing estimates

Reasons to buy

  • Obtain a better understanding of the quantitative value of Net Present Value Model: BeiGene Ltd’s BGB-16673.
  • Access another data source to use in the valuation of Net Present Value Model: BeiGene Ltd’s BGB-16673.
  • Create or support internal NPV models to improve accuracy.
  • Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.

What our clients have to say

More Reports

View More Reports